Start-Up Quarterly Statistics, Q1 2012
This article was originally published in Start Up
Executive Summary
Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.
You may also be interested in...
Shire Buys FerroKin BioSciences To Further Hematology Strategy
Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.
Acorda Expands Pipeline With Neuronex And New Ampyra Indications
Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.
Verastem Joins The Public Markets With A Strong IPO
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.